Abstract: Provided is a portable automated chest-abdominal compression (CC-AC) device used in confined spaces and a manipulation method thereof, comprising: a compression mechanism having a strap fixing module, a compression plate connected to the strap fixing module and a compression piston arranged on one side of the compression plate; a detection module having a displacement sensor and a pressure sensor; a control module receiving compression depth and pressure, and obtaining a compensation value of time of a single compression according to the compression depth and a target depth, thereby controlling an action of a driving mechanism during the CC process; constructing an abdominal mechanics model according to the compression depth and pressure, and compensating the compression depth according to the target pressure by using the abdominal mechanics model, thereby controlling the action of the driving mechanism during the AC process.

Abstract: An optical film set is disclosed. The optical film set including an optical film. The optical film includes a base and multiple light-guiding structures. The base has a light entrance surface and a light exit surface opposite to each other. The light-guiding structures are disposed on the light entrance surface of the base. Each of the light-guiding structures has two light-guiding surfaces opposite to each other. An included angle is between the each of the two light-guiding surfaces and a normal of the light entrance surface, and an angle range of the included angle is larger than 0 degrees and less than 25 degrees. A display device having the optical film set is also disclosed.

Abstract: Systems and methods for wireless communications are disclosed herein. A base station sends, to a wireless communication device, a first number of Transmitted Precoding Matrix Indicators (TPMI) codewords corresponding to a second number of codebook-based uplink transmissions of the wireless communication device. The first number being greater or equal to 1. The second number being greater or equal to 1. The first number of TPMI codewords correspond to an uplink transmission set. The uplink transmission set including the second number of the uplink transmissions. The base station receives, from the wireless communication device, the codebook-based uplink transmissions transmitted based on the TPMI codewords.

Abstract: A power battery comprises a first battery cell group and a second battery cell group that are not equal in electromotive force and connected in series. The heating system comprises an inverter, an alternating-current motor, and a first controller. Midpoints of three bridge arms of the inverter are connected to head ends of three-phase coils of the motor in a one-to-one correspondence manner, and tail ends of the motor are connected together to form a neutral point. The neutral point is connected to a first connection point by means of a connection line, and the first connection point is a connection point between the first and second battery cell groups. The first controller is used for inputting a driving signal to the inverter. The first battery cell group, the second battery cell group, the inverter, the motor, and the connection line form an alternating-current self-heating loop.

Abstract: A power battery comprises a first cell group and a second cell group connected in series. The heating system comprises an inverter, an AC motor, a first controller, and a plurality of connection lines. The midpoints of three bridge arms of the inverter are connected to the head ends of three-phase coils of the AC motor in a one-to-one correspondence. The tail ends of the AC motor are connected together to form a neutral point. First ends of the connection lines are connected to the neutral point of the AC motor. Second ends of the connection lines are connected to a connection point between the first cell group and the second cell group. The first controller is configured to input a drive signal to the inverter. The first cell group, the second cell group, the inverter, the AC motor, and the connection lines form an AC self-heating loop.

Abstract: The present invention relates to a functional cyclic olefin polymer obtained from hydrogenation of a cyclic olefin polymer, wherein the cyclic olefin polymer comprises at least a monomeric unit A? derived from a monomer A having a norbornene ring and a polar functional group, wherein the amount of the monomeric unit A? is in the range of from 20% to 100% by mole, 50% to 100% by mole, from 60% to 100% by mole, or from 70% to 100% by mole, based on the total amount of the monomeric units of the cyclic olefin polymer. The present invention further relates to a process for producing the functional cyclic olefin polymer, a composition comprising the functional cyclic olefin polymer, and the use of the functional cyclic olefin polymer. The functional cyclic olefin polymer of the present invention exhibits improved properties, especially in terms of mechanical properties and barrier properties.

Abstract: A spatial illumination or lighting system based on a light color target has a control device and an actuating device, wherein the control device is configured to interact with a user and communicates with the actuating device, the control device receives identity identification information about the illuminated object input by the user, detects real-time light color data of the object and feeds the detection result back to the user, and sends the identity identification information about the object, the detection result and the light color target to the actuating device. The actuating device is arranged in the space or place, configured to communicate with the control device and implement lighting for the illuminated object: it receives the identification information, the detection result and the light color target of the object, calculates a comprehensive adjustment parameter corresponding to the object, and illuminates the object to achieve the desired light color target.

Abstract: A heating system for heating a battery, includes an inverter including three bridge arms, an alternating current motor, a first controller, and a connection line. A positive electrode of the battery connects to upper bridge arms of the inverter. A negative electrode of the battery connects to lower bridge arms of the inverter. Midpoints of the three bridge arms connects to head ends of three coils of the alternating current motor respectively. Tail ends of the three coils connects together as a neutral point. A first end of the connection line connects to the neutral point, and a second end of the connection line connects to the battery. The first controller inputs a drive signal to the inverter. The battery, the inverter, the alternating current motor, and the connection line form an alternating current self-heating loop. A heating device connects to the connection line, and heats the battery.

Abstract: The present disclosure provides methods for generating MAGE-B2 specific T cells and compositions comprising engineered MAGE-B2-specific T cell receptors. Further provided are methods of treating cancer comprising administering the MAGE-B2-specific T cells.

Abstract: Novel combination therapies involving nitroxoline, its analogue or pharmaceutically acceptable salt thereof with at least one additional anti-cancer chemotherapy or immunotherapy agent are described. Related kits, pharmaceutical compositions and methods of production are also described.

Abstract: Provided are a nitroxoline prodrug and a use thereof. Specifically, provided are a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a preparation method therefor, a composition containing the compound, and a use thereof in the preparation of anti-infective and antitumor drugs, and definitions of groups in formula (I) are as stated in the specification. The compound represented by formula (I) has better pharmacokinetic parameters such as solubility, blood medicine concentration, or half-life period than nitroxoline. The compound represented by formula (I) can reduce the frequency of drug administration, and has potential for application in other fields other than the field of urinary tracts.

Abstract: This disclosure provides for peptides useful for vaccination and other applications, engineered T cell Receptors (TCRs), cells comprising the peptides and TCRs, and methods of making and using the peptides and TCRs. The current disclosure relates to TCRs that specifically recognize SARS-Cov-2 HLA-A2 restricted peptide from membrane glycol-protein (MGP), MGP-65: FVLAAVYRI (SEQ ID NO:22).

Abstract: A waterproof shoe and a manufacturing method for the waterproof shoe are disclosed. The waterproof shoe includes a waterproof shoe upper, a sealing layer and a shoe sole. A bottom portion of the waterproof shoe upper is open and is provided with a connecting member for limiting a periphery of the bottom portion of the waterproof shoe upper from extending outwardly. The connecting member connects a plurality of positions on the periphery of the bottom portion of the waterproof shoe upper. The sealing layer is injection-molded at the bottom portion of the waterproof shoe upper and penetrates into the periphery of the bottom portion of the waterproof shoe upper. The sealing layer and the waterproof shoe upper are enclosed to form a waterproof shoe cover with a sealed bottom portion.

Abstract: The current disclosure fulfills a need in the art by providing methods and compositions for treating and vaccinating individuals against cancer. Accordingly, aspects of the disclosure relate to an isolated peptide comprising at least 70% sequence identity to a peptide of SEQ ID NO: 1 or 2. In some embodiments, the peptide comprises at least 6 contiguous amino acids of a peptide of SEQ ID NO:1 or 2. Further aspects relate to pharmaceutical compositions comprising the isolated peptide, nucleic acids encoding the peptide, and expression vectors and host cells comprising the nucleic acids of the disclosure. Also provided is an in vitro isolated dendritic cell comprising a peptide, nucleic acid, or expression vector of the disclosure.

Abstract: Provided herein are tumor-antigen VCX/Y specific peptides and engineered VCX/Y specific T cell receptors. Also provided herein are methods of generating VCX/Y-specific immune cells and their use for the treatment of cancer. In addition, the VCX/Y-specific peptides may be used as a vaccine.

Abstract: The current disclosure fulfills a need in the art by providing methods and compositions for treating and vaccinating individuals against cancer. Accordingly, aspects of the disclosure relate to an isolated peptide comprising at least 70% sequence identity to a peptide of Table 1. In some embodiments, the peptide comprises at least 6 contiguous amino acids of a peptide of Table 1. Further aspects relate to pharmaceutical compositions comprising the isolated peptide, nucleic acids encoding the peptide, and expression vectors and host cells comprising the nucleic acids of the disclosure. Also provided is an in vitro isolated dendritic cell comprising a peptide, nucleic acid, or expression vector of the disclosure.

Abstract: The present invention discloses a nitroxoline derivative, a preparation method therefor, and use thereof. Specifically, the present discloses a compound as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing same, and use thereof in treating infectious diseases or cancers. The compound of the present invention has excellent anti-tumor activity and antibacterial activity, and can be developed into a drug for treating tumors and infectious diseases. The definition of each group in general formula (I) is the same as that in the description.

Abstract: Pharmaceutical compositions comprising nitroxoline lysinate, a preparation method therefor and a use thereof. The pharmaceutical compositions comprise a first layer and a second layer. The first layer comprises, based on the total weight of the first layer, 40%-70% of active pharmaceutical ingredient, 10%-30% of filler, 5%-12% of disintegrant, 0.5%-2% of lubricant, 0.1%-1.5% of glidant and 10%-20% of alkaline substance. The second layer comprises, based on the total weight of the second layer, 40%-70% of active pharmaceutical ingredient, 10%-30% of filler, 10%-35% of sustained-release material, 0.1%-2% of lubricant and 0.1%-2% of glidant. The active pharmaceutical ingredient is selected from one or more of nitroxoline lysinate, nitroxoline lysinate crystalline form and nitroxoline lysinate solvate. The pharmaceutical compositions can achieve the purpose of burst release at an early stage and sustained and slow release at a later stage.

Abstract: This disclosure provides for engineered T cell Receptors (TCRs), cells comprising the TCRs, and methods of making and using the TCRs. The current disclosure relates to TCRs that specifically recognize epitope(s) from tumor antigen COL6A3. Accordingly, aspects of the disclosure relate to an engineered T-cell Receptors (TCRs), nucleic acids encoding the TCRs, and cells comprising the nucleic acids and TCRs. Also provided are compositions comprising the cells, nucleic acids, or engineered TCRs of the disclosure, methods of making the cells and methods of using the embodiments of the disclosure for therapeutic treatments.

Abstract: Provided herein are tumor-antigen VCX/Y specific peptides and engineered VCX/Y specific T cell receptors. Also provided herein are methods of generating VCX/Y-specific immune cells and their use for the treatment of cancer. In addition, the VCX/Y-specific peptides may be used as a vaccine.